1 min read|54 words
𧬠The biotech industry stands at a critical turning point as drug development costs reach $2.6 billion per new therapy. Veteran exec Jeremy Levin explains why companies must fundamentally rethink their business models to navigate regulatory complexity and funding challenges. The future of breakthrough therapies depends on strategic adaptation.
Read the full article on GMJ Newsroom β
Was this article helpful?
